ArticleJournal of cancer research and clinical oncology2023
Wilms tumor 1 associated protein promotes epithelial mesenchymal transition of gastric cancer cells by accelerating TGF-β and enhances chemoradiotherapy resistance.
Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 34 citations in OpenAlex.
- The relevance of mJournal of cancer research and clinical oncology · 2026Review
- Regulation of mCell biology and toxicology · 2026Review
- RNA mCell biology and toxicology · 2026Review
- The mechanistic role of Wilms tumor 1-associated protein in cancer pathogenesis, immunity, immunotherapy, and therapy resistance.Investigational new drugs · 2026Review
- Review
- Targeting RNA adenosine editing and modification enzymes for RNA therapeutics.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance.Signal transduction and targeted therapy · 2025Review
- The Oncogenic Role of UBXN1 in Gastric Cancer Is Attributed to the METTL16-Mediated m6A Methylation and Histone Modifications.Cancer medicine · 2025Article
- Exploring m6A modifications in gastric cancer: from molecular mechanisms to clinical applications.European journal of medical research · 2025Review
- Migrasome-Related Prognostic Genes in Gastric Cancer: A Transcriptomic and Immunotherapeutic Analysis.OncoTargets and therapy · 2025Article
- Regulation of RNA methylation linked to drug resistance in gastric cancer.Frontiers in cell and developmental biology · 2025Review
- FTO is Associated with Patient Prognosis and Immune Infiltrates in Gastric Cancer and Regulates TGF-β Expression.Combinatorial chemistry & high throughput screening · 2025Article
- The inspiration of methyltransferase in RNA methylation modification for targeted therapy of malignant tumors.Frontiers in immunology · 2025Review
- m6A epitranscriptomic modification in hepatocellular carcinoma: implications for the tumor microenvironment and immunotherapy.Frontiers in immunology · 2025Review
- Reversal of chemotherapy resistance in gastric cancer with traditional Chinese medicine as sensitizer: potential mechanism of action.Frontiers in oncology · 2025Review
- Advances in research on RNA methylation and cancer radiotherapy resistance.Frontiers in oncology · 2025Review
- WTAP-mediated m6A regulation in digestive system cancers: from molecular mechanisms to therapeutic strategies.American journal of cancer research · 2025Review
- HJURP modulates cell proliferation and chemoresistance via the MYC/TOP2A transcriptional axis in gastric cancer.Frontiers in molecular biosciences · 2025Article
- Research progress on m6A and drug resistance in gastrointestinal tumors.Frontiers in pharmacology · 2025Review
- Epitranscriptomic RNA mAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purposeWilms tumor 1 associated protein (WTAP) is a key RNA n6-methyladenosine (m6A) methylase, which predicts the occurrence of many diseases, such as liver fibrosis formation, coordinating cancer stem cell function, and promoting tumor development. Gastric cancer (GC) is one of the most common malignant tumors worldwide. However, the role of WTAP in GC development and drug resistance remains unclear.
methodsBiological methods and data analysis were used to investigate the expression of WTAP in gastric carcinoma tissue. The expression of transforming growth factor-beta (TGF-β) and epithelial mesenchymal transition (EMT) in GC cells were detected by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and Western blot (WB) with WTAP overexpression cell lines and WTAP knockout cell lines. Gradient concentrations of cisplatin (DDP), gradient cyclophosphamide (CTX), or radiation X-rays were added to WTAP overexpression cell lines and WTAP knockdown cell lines to observe the change of cell viability after radiotherapy and chemotherapy treatment.
resultsThe expression of WTAP in gastric carcinoma tissue significantly increased as determined by bioinformatics analysis, and a high expression of WTAP was closely associated with poor prognosis of gastric cancer patients. Overexpression of WTAP promoted migration and EMT of GC cells and promoted the expression of TGF-β and the stability of mRNA. WTAP knockdown inhibited migration of GC cells and decreased TGF-β expression and stability of mRNA. In addition, WTAP promoted multiple chemotherapy resistance and radiotherapy resistance in GC.
conclusionsWTAP is a potential predictive biomarker for GC. Our findings revealed a novel mechanism by which WTAP regulates chemoradiotherapy resistance, extending the understanding of the m6A machinery in TGF-β induced EMT and metastasis in GC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.